Denmark-listed drugs developer H Lundbeck has invested £10.3m ($16m) in UK-based Proximagen Group as part of a strategic partnership to treat central nervous system (CNS) disorders.

Lundbeck is buying 5.7 million shares at £1.80 each, a 36% premium over its six-month average price before the offer.

A steering committee from both companies will focus on developing three of Proximagen’s programmes, with the aim of identifying novel innovative therapies for serious diseases such as epilepsy, pain and inflammatory disorders. Lundbeck…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?